Skip to main content
letter
. 2013 Aug 30;3(8):e138. doi: 10.1038/bcj.2013.40

Figure 1.

Figure 1

SAR302503 can efficiently inhibit the proliferation of native and AC220-resistant variants of FLT3-ITD. (a) Dose–response sigmoidal curve showing the cellular proliferation of BAF3 cells expressing FLT3 and its kinase domain AC220 resistant variants at different concentrations of SAR302503. IC50 values for each cell lines are indicated in parenthesis. (b) Bar graph showing relative fold difference in the IC50 values of FLT3 mutants normalized to native FLT3-ITD. (c) Immunoblot analysis showing the kinase activity of FLT3 and its kinase domain drug resistant variants against SAR302503 at different concentrations. Blots were probed using anti-phospho-FLT3, anti-phospho-STAT5, anti-FLT3 and anti-STAT5 antibody on the crude lysates from BAF3 cells expressing FLT3 and its drug resistant variants. Please note the reduced autophosphorylation in variants ITD-D835F/Y, ITD-F691L and ITD-D839G, whereas ITD-D842H showing increased autophosphorylation in untreated samples as compared with native FLT3-ITD.